Active Clinical Trials

Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM).

By April 24, 2017 No Comments

Condition

Mesothelioma, Malignant

Estimated Enrollment: 108

Age Group: 18 Years to 99 Years   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment

Study ID Numbers: MORAb-009-201

Study First Received: January 14, 2015

Last Updated: February 8, 2017

Estimated Primary Completion Date: September 2017

 

Primary Outcome Measures:

Overall Survival (OS)|Progression Free Survival (PFS)|Objective Response Rate [ORR]|Duration of response (DR)|Disease control rates (DCR)|Duration of disease control (DDC)|Health related quality of life (QOL)|Duration of Performance Status Maintenance (DPSM)|Safety and tolerability as a measure of number of participants with Adverse Events (AEs)/Serious Adverse Events (SAEs)|Pharmacokinetic (PK) and pharmacodynamic (PD) profile

Sponsors and Collaborators:

Morphotek

Website Link: https://ClinicalTrials.gov/show/NCT02357147

Leave a Reply

Call Now